Antibacterial activity of methanol extract of Artocarpus heterophyllus fruit peel against ESBL- and carbapenemase-producing bacteria from immunocompromised patients
Cell Biology and Development · 03.07.2026 · 10 (1)
DOI: 10.13057/cellbioldev/v100104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology and Development, online erschienen am 03.07.2026. Verfasst von G. C. AGU und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Agu GC, Onabanjo MA, Adekola HA, Agu NC, Adeyemi JO, Afolabi OT, Balogun-Abiola HT, Raji-Idowu FO, Osiyemi EO, Boniface BB. 2026. Antibacterial activity of methanol extract of Artocarpus heterophyllus fruit peel against ESBL- and carbapenemase-producing bacteria from immunocompromised patients. Cell Biol Dev 10 (1): v100104. https://doi.org/10.13057/cellbioldev/v100104. Antimicrobial resistance among Gram-negative bacteria poses a major threat to immunocompromised patients. This cross-sectional study evaluated 185 urine samples from HIV-positive, diabetic, and oncology outpatients at Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria. Isolates were identified by VITEK 2 and 16S rRNA sequencing, screened for antibiotic susceptibility by Kirby-Bauer disc diffusion, and assessed phenotypically and by multiplex PCR for ESBL (CTX-M, TEM, SHV) and carbapenemase (VIM, IMP, NDM-1) genes. The antibacterial activity of the methanol extract of Artocarpus heterophyllus fruit peel (MAH), characterized by phytochemical screening and GC-MS, was evaluated against genotypically confirmed multidrug-resistant (MDR) isolates by disc diffusion, with MIC/MBC determined by broth macrodilution. Of 254 Gram-negative isolates, 148 (58.3%) were MDR, with Escherichia coli (44.6%) and Klebsiella pneumoniae (28.4%) predominating. ESBL production was observed in 39.9% (TEM in 66.7%), and 54.1% screened positive for carbapenemase, with VIM the only gene detected. MAH contained phenols, tannins, flavonoids, saponins, terpenoids, cardiac glycosides, and coumarins; GC-MS identified 24 compounds, dominated by benzoic acid methyl ester (22.37%). MAH showed concentration-dependent inhibition (50-500 mg/mL), with MIC and MBC values of 50-200 and 200-400 mg/mL, respectively, for susceptible isolates. MAH was bactericidal (MBC/MIC ≤ 4) against K. pneumoniae, Pseudomonas spp., and E. coli, bacteriostatic against Enterobacter hormaechei, and inactive against Acinetobacter baumannii, Burkholderia cenocepacia, and Citrobacter koseri. Notably, MAH inhibited a norfloxacin-resistant, ESBL/carbapenemase-positive K. pneumoniae isolate (14.3 mm), exceeding norfloxacin’s zone (4.3 mm). MAH is thus a promising candidate for adjunctive antibacterial therapy against MDR Gram-negative pathogens, warranting bioassay-guided fractionation.
Zitieren
APA
AGU, G. C., ONABANJO, M. A., ADEKOLA, H. A., AGU, N. C., ADEYEMI, J. O., AFOLABI, O. T., BALOGUN-ABIOLA, H. T., RAJI-IDOWU, F. O., OSIYEMI, E. O., & BONIFACE, B. B. (2026). Antibacterial activity of methanol extract of Artocarpus heterophyllus fruit peel against ESBL- and carbapenemase-producing bacteria from immunocompromised patients. Cell Biology and Development, 10(1). https://doi.org/10.13057/cellbioldev/v100104
Vancouver
AGU GC, ONABANJO MA, ADEKOLA HA, AGU NC, ADEYEMI JO, AFOLABI OT, et al. Antibacterial activity of methanol extract of Artocarpus heterophyllus fruit peel against ESBL- and carbapenemase-producing bacteria from immunocompromised patients. Cell Biology and Development. 2026;10(1). doi:10.13057/cellbioldev/v100104
BibTeX
@article{AGU2026,
author = {AGU, G. C. and ONABANJO, M. A. and ADEKOLA, H. A. and AGU, N. C. and ADEYEMI, J. O. and AFOLABI, O. T and BALOGUN-ABIOLA, H. T. and RAJI-IDOWU, F. O. and OSIYEMI, E. O. and BONIFACE, B. B.},
title = {Antibacterial activity of methanol extract of Artocarpus heterophyllus fruit peel against ESBL- and carbapenemase-producing bacteria from immunocompromised patients},
journal = {Cell Biology and Development},
year = {2026},
volume = {10},
number = {1},
doi = {10.13057/cellbioldev/v100104}
}
EUVIMED